title: The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation.
abstract: We investigated the influence of the site of administration of DNA vaccine on the induced immune response. DNA vaccines were administered by electroporation at three different sites: tibial cranial muscle, abdominal skin and ear pinna. Aiming to draw general conclusions about DNA vaccine delivery, we successively used several plasmids encoding either luciferase and ovalbumin as models or gp160 and P1A as vaccines against HIV and P815 mastocytoma, respectively. Low levels and duration of luciferase transgene expression were observed after electroporation of the abdominal skin, partly explaining its lower immunogenic performance as compared to the other sites of administration. Analyses of OT-I CD8+ and OT-II CD4+ T cell responses highlighted the differential impact of the delivery site on the elicited immune response. Muscle electroporation induced the strongest humoral immune response and both muscle and ear pinna sites induced cellular immunity against gp160. Ear pinna delivery generated the highest level of CTL responses against P1A but electroporation of muscle and ear pinna were equally efficient in delaying P815 growth and improving mice survival. The present study demonstrated that the site of administration is a key factor to be tested in the development of DNA vaccine.
authors.affiliation: Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, Belgium.
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Vandermeulen
authors.affiliation: Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, Belgium.
authors.forename: Kevin
authors.initials: K
authors.lastname: Vanvarenberg
authors.affiliation: Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
authors.forename: Ans
authors.initials: A
authors.lastname: De Beuckelaer
authors.affiliation: Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
authors.forename: Stefaan
authors.initials: S
authors.lastname: De Koker
authors.affiliation: Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, Belgium.
authors.forename: Laure
authors.initials: L
authors.lastname: Lambricht
authors.affiliation: Université catholique de Louvain, Ludwig Institute for Cancer Research, Brussels Branch and de Duve Institute, Brussels, Belgium.
authors.forename: Catherine
authors.initials: C
authors.lastname: Uyttenhove
authors.affiliation: Immunology-Vaccinology, Department of Infectious and Parasitic Diseases, Fundamental and Applied Research for Animals & Health (FARAH), Faculty of Veterinary Medicine, University of Liège, Liège, Belgium.
authors.forename: Anca
authors.initials: A
authors.lastname: Reschner
authors.affiliation: Immunology-Vaccinology, Department of Infectious and Parasitic Diseases, Fundamental and Applied Research for Animals & Health (FARAH), Faculty of Veterinary Medicine, University of Liège, Liège, Belgium.
authors.forename: Alain
authors.initials: A
authors.lastname: Vanderplasschen
authors.affiliation: Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium.
authors.forename: Johan
authors.initials: J
authors.lastname: Grooten
authors.affiliation: Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, Brussels, Belgium. Electronic address: veronique.preat@uclouvain.be.
authors.forename: Véronique
authors.initials: V
authors.lastname: Préat
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology; D000005:Abdomen; D000279:Administration, Cutaneous; D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology; D054644:Ear Auricle; D018274:Electroporation; D005260:Female; D015483:HIV Antibodies / Q000097:blood / Q000276:immunology; D019302:HIV Envelope Protein gp160 / Q000235:genetics; D015497:HIV-1 / Q000276:immunology; D006614:Hindlimb; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D008156:Luciferases / Q000235:genetics; D008810:Mice, Inbred C57BL; D018482:Muscle, Skeletal; D010957:Plasmids; D012867:Skin / Q000276:immunology; D014611:Vaccination / Q000379:methods*; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015483:HIV Antibodies; D019302:HIV Envelope Protein gp160; D019444:Vaccines, DNA; D008156:Luciferases
keywords: DNA vaccine; Delivery site; Electroporation; HIV vaccine; Tumor vaccine